SCHEMBL4715587

SCHEMBL4715587

Cc1cc2c(Nc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)c(F)cc(F)c2cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.50
BCR P11274 5/20 0.50
TRPV1 Q8NER1 10/20 0.48
FAAH O00519 1/20 0.41
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
GLA P06280 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715948 0.86 TRPV1 (0.53) ABL1BCRTRPV1FAAHTHRB
SCHEMBL4716125 0.86 TRPV1 (0.53) ABL1BCRTRPV1FAAHTHRB
SCHEMBL4715954 0.85 PSEN1 (0.39) ABL1BCRTHRBCYP2D6MAPK1
SCHEMBL4715624 0.82 KDM4E (0.35) TRPV1THRBALDH1A1CYP1A2MAPK1
SCHEMBL4715973 0.79 TRPV1 (0.57) ABL1BCRTRPV1FAAHTHRB
SCHEMBL4715969 0.77 TRPV1 (0.69) ABL1BCRTRPV1FAAHTHRB
SCHEMBL4717973 0.74 TRPV1 (0.40) ABL1BCRTRPV1TP53
SCHEMBL4718519 0.73 ALDH1A1 (0.40) TRPV1FAAHMEN1USP2ALDH1A1
SCHEMBL4717847 0.73 ABL1 (0.51) ABL1BCRFAAHMAPK1
SCHEMBL1013728 0.73 ABL1 (0.76) ABL1BCRTRPV1FAAHTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ABL1 3380/4885BCR 2892/4885TRPV1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.